So a bit more detail on.......>

GLOBAL MARKET/OPINION: So a bit more detail on those Gilead headlines - the

primary endpoint that was successful in the trial was on the *duration* of

treatment, not on the efficacy of the drug itself.

- "The study demonstrated that patients receiving a 10-day treatment course of

remdesivir achieved similar improvement in clinical status compared with those

taking a 5-day treatment course"

- And Gilead themselves warn that the drug remains unproven: "Remdesivir [...]

has not yet been demonstrated to be safe or effective for the treatment of

COVID-19"

- So the study will help with the efficient and effective use of drug supply,

rather than proving the drug is a successful treatment.

- NIAID are due to be holding a briefing on the results - but timings are

unknown at this stage.